Skip to main content

Table 6 Comparison with recent US and German studies

From: A new paradigm evaluating cost per cure of HCV infection in the UK

Patients characteristics Current study (n = 154) Stahmeyer et al. (GER) [35] (n = 858)* Bichoupan et al. (US) [17] (n = 147)
Age, years [Mean, (SD)] 49.6 (9.0) 49.2 (11.2) 56 (IQR = 51–61)
Gender, Male [%] 73.4 58 68
Ethnicity, %    
 Caucasian [%] 94.20 % 97.30 % Not reported
 Asian [%] 2.70 % 0.90 % Not reported
 African [%] 1.30 % 0.80 % 19 %
 Hispanic [%] Not reported 0.50 % Not reported
 Other [%] 1.80 % Not reported Not reported
SVR rate by therapy    
 BOC [%] 60.8 58.1 Not reported
 TVR [%] 63.1 68.4 44
Cirrhosis [%] 21.40 % Not reported 36 %
Prior non-responders [%] 22.10 % Not reported 46 %
Cost drivers    
 Drug costs 94.60 % 94.6–97.7 % 89 %
 PIs 68.30 % Not reported Not reported
 TVR Not reported Not reported 61
 PegIFN 19.50 % Not reported 24 %
 RBV 6.80 % Not reported 4 %
Outpatient and inpatient care (incl AEs & follow-up) 5.40 % 5.4-3.3 % 8 %
Cost per SVR ($)    
 Treatment naïve 56,576 73,473–82,756 Not reported
 Relapsers 58,353 78,529–93,758 Not reported
 Non-responders 125,125 127,1049–132,204 Not reported
 Overall Not reported Not reported 189,000
  1. *Costs from Stahmeyer et al. were converted from euros to US dollars (conversion rate: €1 = $1.0985 based on European Central Bank exchange rates, March 2015)